Stock AKTX AKARI THERAPEUTICS, PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.185 USD -0.42% Intraday chart for Akari Therapeutics, Plc +1.61% -62.02%
Apr. 24 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Apr. 23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 24.82 36.77 71.18 71.4 34.98 17.64
Enterprise Value (EV) 1 19.37 31.03 57.12 62.03 21.73 13.79
P/E ratio -1.47 x -1.75 x -3.42 x -3.69 x -1.65 x -1.53 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -0.86 x -1.83 x -3.35 x -3.6 x -0.94 x -0.82 x
EV / FCF -0.93 x -6.33 x -5.01 x -5.49 x -3.6 x -0.82 x
FCF Yield -107% -15.8% -20% -18.2% -27.8% -121%
Price to Book 7.98 x -22.2 x 7.58 x 12.9 x 19.5 x -90.2 x
Nbr of stocks (in thousands) 790 1,050 1,924 2,380 3,722 5,653
Reference price 2 31.40 35.00 37.00 30.00 9.398 3.120
Announcement Date 4/23/19 3/31/20 4/21/21 5/16/22 5/1/23 3/29/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -22.66 -16.94 -17.07 -17.21 -23.08 -16.8
EBIT 1 -22.69 -16.96 -17.08 -17.21 -23.09 -16.81
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -16.47 -17.11 -17.08 -17.42 -17.75 -10.01
Net income 1 -16.47 -17.11 -17.08 -17.42 -17.75 -10.01
Net margin - - - - - -
EPS 2 -21.38 -20.00 -10.81 -8.119 -5.685 -2.045
Free Cash Flow 1 -20.73 -4.906 -11.4 -11.31 -6.045 -16.74
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/23/19 3/31/20 4/21/21 5/16/22 5/1/23 3/29/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 Q4 2023 Q2
Net sales - - -
EBITDA - - -
EBIT - - -
Operating Margin - - -
Earnings before Tax (EBT) -5.68 - -
Net income -5.68 - -
Net margin - - -
EPS 1 - - -
Dividend per Share - - -
Announcement Date 9/27/22 5/1/23 9/29/23
1USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5.45 5.73 14.1 9.36 13.2 3.85
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -20.7 -4.91 -11.4 -11.3 -6.04 -16.7
ROE (net income / shareholders' equity) -163% -2,555% -364% -233% -483% -1,281%
ROA (Net income/ Total Assets) -76.5% -143% -101% -82% -113% -116%
Assets 1 21.53 11.96 16.87 21.26 15.67 8.664
Book Value Per Share 2 3.940 -1.580 4.880 2.330 0.4800 -0.0300
Cash Flow per Share 2 6.890 5.100 7.310 3.930 3.560 0.5800
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/23/19 3/31/20 4/21/21 5/16/22 5/1/23 3/29/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKARI THERAPEUTICS, PLC Stock Akari Therapeutics, Plc
-62.02% 9.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.67% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-8.54% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AKTX Stock
  4. Financials Akari Therapeutics, Plc